This study aimed to investigate the clinicopathological characteristics, treatment patterns, and survival outcomes of hormone receptor (HR)-low positive (1%-10%) breast cancer, with a focus on evaluating the prognostic impact of endocrine therapy (ET) and its interplay with HR-low positive categories (ER-low/PR-low, ER-low/PR-negative, ER-negative/PR-low).
